Posts tagged NASDAQ:URGN
Ladenburg starts UroGen Pharma at buy; PT $50

Ladenburg Thalmann initiated coverage of UroGen Pharma (NASDAQ:URGN) with a “buy” rating and $50 price target. The stock closed at $37.21 on Dec. 29.

Read More